专题:Melanoma and MAPK Pathways

This cluster of papers focuses on the mammalian MAP kinase signaling pathways, particularly their role in cancer, with a specific emphasis on melanoma. It covers the genetic mutations, targeted therapies, resistance mechanisms, and the impact of MAP kinase pathways on cell proliferation and immune response.
最新文献
MetInfilt: A prospective trial highlighting the importance of the histological growth pattern in brain metastases

article Full Text OpenAlex

0061 Interstitial granulomatous dermatitis: A case highlighting possible associations with myeloma and TNF-α inhibitor therapy

article Full Text OpenAlex

0838 Rare onset of combination immunotherapy induced vitiligo-like depigmentation in patient with metastatic melanoma: A case report

article Full Text OpenAlex

Improved prediction of MAPKi response duration in melanoma patients using genomic data and machine learning

article Full Text OpenAlex

MelanoDB: A dataset of clinical and molecular features of patients with advanced melanoma treated with MAPK inhibitors

article Full Text OpenAlex

Tyrosine-Kinase Inhibitors

book-chapter Full Text OpenAlex

Region-specific roles of stress-activated protein kinase MKK7 in the developing and maturing murine brain

article Full Text OpenAlex

Clinical and histopathological characteristics of melanomas in Asians under age 40

article Full Text OpenAlex

A Full-Scaled Perspective of K-Ras4B Transformations Modulated by Oncogenic G12D and Phosphorylation in Phase-Segregated Membrane

article Full Text OpenAlex

Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial

article Full Text OpenAlex

近5年高被引文献
Immune checkpoint inhibitors in melanoma

review Full Text OpenAlex 913 FWCI27.145

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor

article Full Text OpenAlex 516 FWCI30.744

Diversity and versatility of p38 kinase signalling in health and disease

review Full Text OpenAlex 477 FWCI11.155

Acquired Resistance to KRASG12C Inhibition in Cancer

article Full Text OpenAlex 468 FWCI55.651

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

article Full Text OpenAlex 466 FWCI74.278

Cutaneous melanoma

review Full Text OpenAlex 409 FWCI28.733

Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation

article Full Text OpenAlex 408 FWCI27.086

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

article Full Text OpenAlex 389 FWCI58.685

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

article Full Text OpenAlex 353 FWCI30.848

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

article Full Text OpenAlex 343 FWCI32.502